Systemically healthy periodontitis patients were recruited in this single-blind, split-mouth, randomized controlled clinical trial. After SRP, PDT was applied at probing depth (PD) ≥ 4 mm at test quadrant. At baseline, 3rd month and 6th month, clinical parameters and cytokine pattern in gingival crevicular fluids (GCFs) were analysed.
Periodontal parameters and cytokine IL-1β, IL-6, IL-8, TNF-α, MMP-8 levels were analysed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
51
After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
Changes from baseline probing depth at 3rd month and 6th month
Clinical probing depth in mm
Time frame: 3 months and 6 months
Changes from baseline clinical attachment level at 3rd month and 6th month
Clinical attachment level in mm
Time frame: 3 months and 6 months
Changes from baseline gingival recession level at 3rd month and 6th month
Gingival recession level in mm
Time frame: 3 months and 6 months
Changes from baseline bleeding score at 3rd month and 6th month
Bleeding score in percentage
Time frame: 3 months and 6 months
Changes from baseline Interleukin-1 level at 3rd month and 6th month
Interleukin-1 level in gingival crevicular fluid
Time frame: 3 months and 6 months
Changes from baseline Interleukin-6 level at 3rd month and 6th month
Interlekin-6 level in gingival crevicular fluid
Time frame: 3 months and 6 months
Changes from baseline Interleukin-8 level at 3rd month and 6th month
Interleukin-8 level in gingival crevicular fluid
Time frame: 3 months and 6 months
Changes from baseline Tumour necrosis factor-alpha level at 3rd month and 6th month
Tumour necrosis factor-alpha level in gingival crevicular fluid
Time frame: 3 months and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Changes from baseline Matrix metalloproteinase-8 level at 3rd month and 6th month
Matrix metalloproteinase-8 level in gingival crevicular fluid
Time frame: 3 months and 6 months